微生物与感染
2025年1月9日 星期四   首页 |  主编心语 |  期刊介绍 |  编委阵容 |  投稿指南 |  出版道德 |  期刊订阅 |  联系我们 | English
微生物与感染  2016, Vol. 11 Issue (5): 287-292    
  论著 本期目录 | 过刊浏览 | 高级检索 |
预测核苷(酸)类似物停药后慢性乙型肝炎复发的生化标记筛查及其临床应用
汪月娥,温潇,陈沛冬,范清琪,汪婷,贾雯,包莹,王嘉颖
上海市静安区中心医院,复旦大学附属华山医院静安分院感染科,上海 200040
Assessment of probable biomarkers predicting relapse of chronic hepatitis B after withdrawal of nucleos(t)ide analogs
WANG Yuee,WEN Xiao,CHEN Peidong,FAN Qingqi,WANG Ting,JIA Wen,BAO Ying,WANG Jiaying
Department of Infectious Diseases,Jing’an District Centre Hospital of Shanghai,Jing’an Branch of Huashan Hospital,Fudan University,Shanghai 200040,China
全文: PDF (1065 KB)   HTML (0)
输出: BibTeX | EndNote (RIS)      
摘要: 为探寻核苷(酸)类似物停药后慢性乙型肝炎复发的相关因素及可能血清标记,收集经核苷(酸)类似物治疗的乙型肝炎病毒e抗原(hepatitis B virus e antigen,HBeAg)阳性或阴性慢性乙型肝炎患者,根据治疗应答对其能否停药进行临床评估,分析达到停药标准患者的临床资料,包括性别,年龄,疗程,HBeAg水平,基线丙氨酸氨基转移酶(alanine aminotransferase,ALT)、HBV DNA,停药时的肝硬度值、HBV表面抗原(HBV surface antigen,HBsAg)水平、白细胞介素21(interleukin 21,IL-21)水平、外周血CD4 IL-21 T细胞频数。结果显示,共47例患者符合停药标准,其中HBeAg阳性26例,HBeAg阴性21例;平均年龄(42.45±14.08)岁。抗病毒疗程平均为(4.60±1.61)年。抗病毒治疗初始ALT值为(174.38±200.84)U/L;基线HBV DNA 为(5.87±1.06)log拷贝/mL;停药时HBsAg精确定量平均为(1 104.82±1 328.11)IU/mL,IL-21平均为(729.82±427.39) pg/mL,CD4 IL-21 T细胞频数平均为(0.79±0.49)%,肝硬度测定F1 27例、F2 16例、F3 4例、F4 0例。共27例患者复发,1年内累积复发率为57.45%。Logistic回归单因素分析提示,慢性乙型肝炎患者停用核苷(酸)类似物后复发与服药总疗程及停药时IL-21水平、CD4 IL-21 T细胞频数、HBsAg水平有关;Logistic回归多因素分析则提示,停药时HBsAg和IL-21水平与复发有关。因此,停药时HBsAg和IL-21水平可作为慢性乙型肝炎患者停用核苷(酸)类似物后复发的预测因素。

服务
把本文推荐给朋友
加入我的书架
加入引用管理器
E-mail Alert
RSS
作者相关文章
汪月娥
温潇
陈沛冬
范清琪
汪婷
贾雯
包莹
王嘉颖
关键词 慢性乙型肝炎复发核苷(酸)类似物白细胞介素21    
Abstract:To evaluate the probable predicting factors and biomarkers associated with the relapse of chronic hepatitis B after withdrawal of nucleos(t)ide analogs, a clinical assessment of patients with chronic hepatitis B, either hepatitis B virus e antigen (HBeAg)-positive or -negative, who had received the treatment of nucleos(t)ide analogs and met the requirement for withdrawal was made. Then the clinical data were collected including sex, age, treatment course, HBeAg level, baseline alanine aminotransferase (ALT) and HBV DNA levels, liver stillness, HBV surface antigen (HBsAg) level, interleukin 21 (IL-21) level and frequency of peripheral blood CD4 IL-21 T cells at the time of withdrawal. Forty seven patients met the requirement for withdrawal. Among them, 26 patients were HBeAg-positive and 21 patients were HBeAg-negative. The mean age was (42.45±14.08) years. The mean treatment course was (4.60±1.61) years. The mean baseline ALT level was (174.38±200.84) U/L. The mean baseline HBV DNA level was (5.87±1.06) log copies/mL. The mean HBsAg level was (1 104.82±1 328.11) IU/mL. The mean IL-21 level was (729.82±427.39) pg/mL. The mean frequency of peripheral blood CD4 IL-21 T cells was (0.79±0.49)%. The liver stillness measurement at the time of withdrawal was F1 in 27 patients, F2 in 16 patients, and F3 in 4 patients. Twenty seven (57.45%) patients relapsed in one year. Single-factor logistic regression analysis showed that the relapse of chronic hepatitis B after withdrawal of nucleos(t)ide analogs was associated with treatment course, IL-21 level, frequency of peripheral blood CD4IL-21 T cells, and HBsAg level. Multi-factor logistic regression analysis showed that HBsAg level and IL-21 level could predict the relapse of chronic hepatitis B after withdrawal of nucleos(t)ide analogs.

Key wordsChronic hepatitis B    Relapse    Nucleos(t)ide analog    Interleukin 21
基金资助:上海市科研计划项目(124119b0900)

通讯作者: 汪月娥   
引用本文:   
汪月娥,温潇,陈沛冬,范清琪,汪婷,贾雯,包莹,王嘉颖. 预测核苷(酸)类似物停药后慢性乙型肝炎复发的生化标记筛查及其临床应用[J]. 微生物与感染, 2016, 11(5): 287-292.
WANG Yuee,WEN Xiao,CHEN Peidong,FAN Qingqi,WANG Ting,JIA Wen,BAO Ying,WANG Jiaying. Assessment of probable biomarkers predicting relapse of chronic hepatitis B after withdrawal of nucleos(t)ide analogs. JOURNAL OF MICROBES AND INFECTIONS, 2016, 11(5): 287-292.
链接本文:  
http://jmi.fudan.edu.cn/CN/     或     http://jmi.fudan.edu.cn/CN/Y2016/V11/I5/287

版权所有 © 2008 《微生物与感染》编辑部
地址:上海市医学院路138号 邮编:200032
Tel:021-54237633 Fax:021-64434224    E-mail:jmi@fudan.edu.cn
本系统由北京玛格泰克科技发展有限公司设计开发  技术支持:support@magtech.com.cn